Charme II

Charme II is a buyout fund managed by Charme Capital Partners, a private equity firm established in 2003 and based in Milan, Italy. Launched in 2009, Charme II focuses on mid-market companies across Europe, specifically targeting sectors such as software, healthcare devices, and supply. The fund seeks to invest in businesses with an enterprise value ranging from €100 million to €500 million, emphasizing growth and transformational change. Charme Capital Partners maintains a strong connection with its investor base to identify new investment opportunities and support the development of its portfolio companies. The firm operates from offices in Milan, London, and Madrid, primarily investing in Italy, Spain, and the United Kingdom.

Tommaso Beolchini

Founding Partner and Member of the Investment Committee and Board Member

Juan Casla

Associate

Francisco Churtichaga

Partner, Member of the Investment Committee and Member of the Board

Martyn Evans

Principal

Matteo Facoetti

Partner and CFO

Julian Huxtable

Partner, Investment Committee Member and Board Member

Vishal Luhana

Investment Manager

Jorge López

Principal

José Megia

Investment Manager

Asier Sanz Mitchell

Investment Manager

Matteo di Montezemolo

Managing Partner CEO and Member of Investment Committee

Bruno Piroso

Investment Manager

Yusuf Saibo

Associate

Luigi Sala

Chairman

Roberto Selvetti

Investment Manager

Ravi Shah

Associate

Pietro Sironi

Junior Investment Manager

Alvaro Trapote

Associate

9 past transactions

Bianalisi

Acquisition in 2021
Provider of laboratory services intended for clinical analysis and specialist diagnostics. The company offers medical laboratory services with a focus on clinical chemistry, pathological anatomy, toxicology, drug abuse treatment, microbiology and virology among others, thereby enabling clients to have efficient, quality and low-cost diagnostic services.

Bianalisi

Private Equity Round in 2021
Provider of laboratory services intended for clinical analysis and specialist diagnostics. The company offers medical laboratory services with a focus on clinical chemistry, pathological anatomy, toxicology, drug abuse treatment, microbiology and virology among others, thereby enabling clients to have efficient, quality and low-cost diagnostic services.

Veritas Intercontinental

Series B in 2020
VERITAS INTERCONTINENTAL, S.L. offers whole genome sequencing related testing and interpretation counselling services. The company conducts genetic tests, including myGenome, which helps to know risk of hereditary diseases, response to certain medications, diseases that could be transmitted to children, and information about consumer’s ancestors; myNewbornDNA, which is for newborns that provides actionable information about genetic diseases that appear during childhood; myCancerRiskDNA, which helps to know increased risk for various types of cancer; and myDiagnostic, which is indicated for patients with symptoms or suspicion of hereditary genetic diseases. The company was founded in 2004 and is based in Madrid, Spain.

Veritas Intercontinental

Series A in 2018
VERITAS INTERCONTINENTAL, S.L. offers whole genome sequencing related testing and interpretation counselling services. The company conducts genetic tests, including myGenome, which helps to know risk of hereditary diseases, response to certain medications, diseases that could be transmitted to children, and information about consumer’s ancestors; myNewbornDNA, which is for newborns that provides actionable information about genetic diseases that appear during childhood; myCancerRiskDNA, which helps to know increased risk for various types of cancer; and myDiagnostic, which is indicated for patients with symptoms or suspicion of hereditary genetic diseases. The company was founded in 2004 and is based in Madrid, Spain.

ATOP

Acquisition in 2017
Atop S.p.A. is an Italian company specializing in the design and manufacture of machines and automatic lines for the production of wound stators and rotors used in electric motors. Founded in 1993 and headquartered in Barberino Val D'Elsa, the company focuses on delivering high technological content in its products, ensuring flexibility, reliability, and ease of use. Atop is dedicated to meeting specific customer needs, offering tailored solutions for complex requirements in the automotive sector. As a subsidiary of I.M.A. Industria Macchine Automatiche S.p.A. since July 2019, Atop continues to enhance its capabilities to serve clients globally.

JD Classics

Acquisition in 2016
JD Classics is the premium Classic Car business, providing restoration, sales and related lifestyle and racing services to its global customer base. Over the past three decades the company has built a world-class reputation for quality, expertise, and passion. JD Classics works for both private and trade customers all over the world, helping its clientele with everything they need for buying/selling, owning and enjoying their cars. This includes sales and after-sales; restoration and upgrading; and a wide-range of racing and lifestyle services.

Igenomix

Acquisition in 2016
Igenomix, S.L. specializes in reproductive genetic diagnosis services for healthcare professionals in the field of reproductive medicine. Founded in 1996 and headquartered in Paterna, Spain, the company has established itself as a global leader in advanced reproductive genetics, operating laboratories in various locations including the United States, Brazil, Japan, and several European and Middle Eastern countries. Igenomix offers a range of specialized services, including pre-implantation genetic diagnosis for single gene disorders, pre-implantation genetic screening for aneuploidy, and endometrial receptivity analysis. Additionally, the company provides non-invasive prenatal testing, sperm aneuploidy testing, carrier genetic testing, and MitoScore, a mitochondrial biomarker. With a strong focus on research and development, Igenomix continues to create innovative tools for reproductive medicine professionals worldwide.

Bellco

Acquisition in 2012
Bellco S.r.l. is an Italian company that specializes in medical devices for renal care, focusing on the treatment of renal failure, multiple organ failure, sepsis, and congestive heart failure. Founded in 1972 and headquartered in Mirandola, Italy, the company offers a wide range of products, including haemodiafiltration therapies, dialysis machines, haemodialysers, blood lines, catheters, concentrates, and sorbent cartridges. Bellco also develops therapeutic systems for acute patients in intensive care, as well as for neonatal patients. The company's commitment to innovation and research enables it to address the evolving needs of patients and healthcare professionals in nephrology, intensive care, and cardiology. It markets its products directly in Italy and has a presence in various countries through branches and distributors, including France, Spain, Belgium, Brazil, China, and Canada. Bellco operates as a subsidiary of Medtronic plc.

Bellco

Venture Round in 2009
Bellco S.r.l. is an Italian company that specializes in medical devices for renal care, focusing on the treatment of renal failure, multiple organ failure, sepsis, and congestive heart failure. Founded in 1972 and headquartered in Mirandola, Italy, the company offers a wide range of products, including haemodiafiltration therapies, dialysis machines, haemodialysers, blood lines, catheters, concentrates, and sorbent cartridges. Bellco also develops therapeutic systems for acute patients in intensive care, as well as for neonatal patients. The company's commitment to innovation and research enables it to address the evolving needs of patients and healthcare professionals in nephrology, intensive care, and cardiology. It markets its products directly in Italy and has a presence in various countries through branches and distributors, including France, Spain, Belgium, Brazil, China, and Canada. Bellco operates as a subsidiary of Medtronic plc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.